- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01035619
Pediatric Pharmacokinetics And Safety Study Of Moxidectin
March 27, 2012 updated by: Pfizer
A Single-Center, Open-Label, Single-Dose Study To Assess The Pharmacokinetics, Safety, And Tolerability Of Moxidectin In Subjects Aged 4 To 11 Years ( >=12 kg) With Or Without Onchocerca Volvulus Infection
The purpose of this study is to measure the amount of moxidectin in subjects' blood and to measure safety.
This study will enroll 36 children aged 4 to 11 years (>=12 kg) with or without Onchocerca volvulus (O volvulus) infection.
O volvulus is the nematode, or roundworm, that causes Onchocerciasis, also known as river blindness.
Each subject will receive a single dose of 4 mg moxidectin (orally administered) and will be followed inpatient from screening through day 13 and as outpatients through month 6.
The study will take place at a single research center.
Study Overview
Study Type
Interventional
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years to 9 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female subjects aged 4 to 11 years, inclusive (weighing >= 12 kg)
- With or without O volvulus infection
Exclusion Criteria:
- Any major illness/condition that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of the study
- Contraindication or hypersensitivity to moxidectin
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Moxidectin
|
Single Dose Moxidectin 4 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The amount of moxidectin in subjects blood, as measured by collecting a number of blood samples from each subject, in which the amount of moxidectin will be measured
Time Frame: 3 months
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The safety and tolerability of a single dose of 4 mg moxidectin in subjects as measured by physical examinations, laboratory tests, vital signs and ECG findings
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2011
Primary Completion (Actual)
April 1, 2011
Study Completion (Actual)
April 1, 2011
Study Registration Dates
First Submitted
December 17, 2009
First Submitted That Met QC Criteria
December 18, 2009
First Posted (Estimate)
December 21, 2009
Study Record Updates
Last Update Posted (Estimate)
March 29, 2012
Last Update Submitted That Met QC Criteria
March 27, 2012
Last Verified
March 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- B1751005
- 3110A1-2201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Onchocerciasis
-
Center for Research on Filariasis and Other Tropical...Active, not recruitingOnchocerciasis, Ocular | LoiasisCameroon
-
Programme National de Lutte contre l'Onchocercose...CompletedOnchocerciasis, Ocular | LoiasisCongo
-
Washington University School of MedicineNational Public Health Institute of LiberiaNot yet recruitingOnchocerciasis | Onchocerciasis, Ocular | Tropical Disease | Onchocercal Subcutaneous Nodule | Onchocerca InfectionLiberia
-
University Hospitals Cleveland Medical CenterWashington University School of MedicineCompleted
-
Washington University School of MedicineCase Western Reserve University; University of Health and Allied SciencesCompleted
-
Medicines Development for Global HealthCompleted
-
University Hospitals Cleveland Medical CenterCompleted
-
Medicines Development for Global HealthActive, not recruitingOnchocerciasisCongo, The Democratic Republic of the
-
Washington University School of MedicineCase Western Reserve University; University of Health and Allied SciencesCompleted
-
Centers for Disease Control and PreventionUniversity of Alabama at Birmingham; Universidad del Valle, GuatemalaCompletedOnchocerciasisGuatemala
Clinical Trials on moxidectin
-
Medicines Development for Global HealthWorld Health OrganizationCompleted
-
Swiss Tropical & Public Health InstitutePublic Health Laboratory Ivo de CarneriCompletedTrichuris Trichiura; InfectionTanzania
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Medicines Development for Global HealthCompleted
-
Jennifer KeiserNational Centre for Parasitology, Entomology and Malaria Control, CambodiaCompletedStrongyloides Stercoralis InfectionCambodia
-
Medicines Development for Global HealthRecruiting
-
Center for Research on Filariasis and Other Tropical...Active, not recruitingOnchocerciasis, Ocular | LoiasisCameroon
-
Washington University School of MedicineNational Public Health Institute of LiberiaNot yet recruitingOnchocerciasis | Onchocerciasis, Ocular | Tropical Disease | Onchocercal Subcutaneous Nodule | Onchocerca InfectionLiberia
-
Medicines Development for Global HealthCompleted
-
Medicines Development for Global HealthActive, not recruitingOnchocerciasisCongo, The Democratic Republic of the